Thirdly, due to a lack of detection of PD-L1 expression on tumor cells, future studies will require the evaluation of the PD-1 and PD-L1 expression levels on tumor-infiltrating lymphocytes as potentially valuable biomarkers. The gene discussed is PDCD1; the disease is neoplasm.